Second-Line and Third-Line Treatment Options for Metastatic HER2+ Breast Cancer

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Atilla Soran, MD, MPH;Kazim Senol;Schlomo Schneebaum;Shigeru Imoto;Carole Mathelin;Alexander Mundinger;Meltem Selam;Vahit Ozmen

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Roman Fabbricatore

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Zeynep Ozlem Soran;Allison Brophy;Lily Kass;Berkay Demirors;Hayeon Kim;Atilla Soran, MD, MPH;John Austin Vargo;Parul Barry

April 20th 2025

Lee Schwartzberg, MD, FACP;Omkar Marathe;Shanta Chawla;Jeffrey L. Vacirca;Kenneth Crist;Howard Franklin;Manuel Modiano

Related Content

April 23rd 2025

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Atilla Soran, MD, MPH;Kazim Senol;Schlomo Schneebaum;Shigeru Imoto;Carole Mathelin;Alexander Mundinger;Meltem Selam;Vahit Ozmen

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Roman Fabbricatore